Antibody Information

General Information of This Antibody

Antibody ID	ANI0QRULO
Antibody Name	Epratuzumab
Brand Name	Lymphocide
Organization	Immunomedics, Inc.; UCB SA
Indication	Acute lymphoblastic leukemia; Systemic lupus erythematosus; Non-Hodgkin lymphoma;
Synonyms	AMG-412; hLL2; IMMU-HLL2; Lymphocide Click to Show/Hide
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-nd
Antigen Name	B-cell receptor CD22 (CD22)	Antigen Info
ChEMBI ID	CHEMBL2108404
PDB ID	5vkk , 5vl3
DrugBank ID	DB04958
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEY NQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS Click to Show/Hide
Heavy Chain Varible Domain	QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEY NQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS Click to Show/Hide
Heavy Chain Constant Domain 1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC Click to Show/Hide
Heavy Chain CDR 1	GYTFTSYW Click to Show/Hide
Heavy Chain CDR 2	INPRNDYT Click to Show/Hide
Heavy Chain CDR 3	ARRDITTFY Click to Show/Hide
Light Chain Sequence	DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTR ESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK Click to Show/Hide
Light Chain Varible Domain	DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTR ESGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK Click to Show/Hide
Light Chain Constant Domain	RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
Light Chain CDR 1	QSVLYSANHKNY Click to Show/Hide
Light Chain CDR 2	WAS Click to Show/Hide
Light Chain CDR 3	HQYLSSWT Click to Show/Hide

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Epratuzumab-cys-tesirine [Phase 1/2 (discontinued)]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Key eligibility: CD22+ (≥20% blasts) B-ALL patients (Ph+ allowed after TKI failure) with ≥5% marrow blasts, ECOG 0-2, adequate organ function (Cr≤1.5mg/dL, LVEF≥45%), WBC<15K/uL. Exclusions: active CNS leukemia, GVHD, recent transplant (<60d), HIV/HepB/C+, ADA+, prior VOD, uncontrolled comorbidities, or recent anticancer therapy (<14d/5 half-lives). Strict contraception required (16 weeks post-treatment). Click to Show/Hide
Administration Dosage	Patients receive ADCT-602 by vein over 30 minutes on day 1. Courses repeat every 21 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR/CRi receive ADCT-602 every 28 days.
*Related Clinical Trial*
NCT Number	NCT03698552	Clinical Status	PHASE1\|\|\|PHASE2
Clinical Description	A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Primary Endpoint	Primary objectives include MTD determination via 3+3 dose escalation (DLTs assessed over 21 days), toxicity incidence (CTCAE-graded), RP2D selection, and CR/CRi rate evaluation (Simon's two-stage design) in relapsed/refractory B-ALL patients.
Other Endpoint	Secondary endpoints comprise ORR, OS, PFS, PK profiling (4 samples within 6h post-dose), and QT interval assessment via EKG monitoring.
Experiment 2 Reporting the Activity Date of This ADC				[2]
*Related Clinical Trial*
NCT Number	NCT03698552	Clinical Status	Phase 1
Clinical Description	A phase 1/2 study to evaluate the safety and anti-tumor activity of ADCT-602 targeting CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Experiment 3 Reporting the Activity Date of This ADC				[3]
Patients Enrolled	R/R B-acute lymphocytic leukemia (ALL).
Administration Dosage	A 3+3 dose-escalation design was used for phase 1. ADCT-602 was initially given IV once every 3 weeks (30 ug/kg, n=3; 60 ug/kg, n=4; 90 ug/kg, n=4); based on the PK data, the administration schedule was later amended to weekly infusions (30 ug/kg, n=3; 40 ug/kg, n=4; 50 ug/kg, n=3).
*Related Clinical Trial*
NCT Number	NCT03698552	Clinical Status	Phase 1
Clinical Description	A phase 1/2 study to evaluate the safety and anti-tumor activity of ADCT-602 targeting CD22 in patients with relapsed or refractory b-cell acute lymphoblastic leukemia.
Primary Endpoint	In this phase 1 study in pts with very heavily pretreated R/R B-ALL with a median of 5 prior lines of therapy and high baseline bone marrow tumor burden, single-agent ADCT-602 was well tolerated with no DLTs noted. Two pts achieved MRD-negative remission. Dose escalation in the weekly schedule continues and 2 additional dose levels (40 ug/kg weekly and 50 ug/kg weekly) are planned. PK data, available for 9 pts treated at every 3-week schedule [30 ug/kg, n=3; 60 ug/kg, n=4; 90 ug/kg, n=2] showed rapid clearance of antibody with mean apparent half-life of <1 day during Cycle 1. This supported transitioning ADCT-602 administration to the weekly dosing. Click to Show/Hide
Experiment 4 Reporting the Activity Date of This ADC				[4]
Patients Enrolled	R/R B-acute lymphocytic leukemia (ALL).
Administration Dosage	A 3+3 dose-escalation design was used for phase 1. ADCT-602 was initially given IV once every 3 weeks (30 ug/kg, n=3; 60 ug/kg, n=4; 90 ug/kg, n=4); based on the PK data, the administration schedule was later amended to weekly infusions (30 ug/kg, n=3; 40 ug/kg, n=4; 50 ug/kg, n=3).
*Related Clinical Trial*
NCT Number	NCT03698552	Clinical Status	Phase 1
Clinical Description	A phase 1/2 study to evaluate the safety and anti-tumor activity of ADCT-602 targeting CD22 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Primary Endpoint	In this phase 1 study in pts with very heavily pretreated R/R B-ALL with a median of 5 prior lines of therapy and high baseline bone marrow tumor burden, single-agent ADCT-602 was well tolerated with one pt with DLT noted at the 50 mg/kg weekly dose level. Notably, all 3 pts treated at this dose level had evidence of clinical activity with 2/3 pts achieving MRD negative CR. Click to Show/Hide

BAY-1862864 [Phase 1]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[5]
Patients Enrolled	Key inclusion criteria: histologically confirmed relapsed/refractory CD22+ NHL with available tissue for CD22 testing; bone marrow involvement <25%; ≥1 prior failed chemo/immunotherapy; ineligible for HDT ASCR; ECOG ≤2; life expectancy ≥12 weeks; adequate organ function; reproductive safety measures; written informed consent
Administration Dosage	Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (2 mg antibody chelator conjugate [ACC]).
*Related Clinical Trial*
NCT Number	NCT02581878	Clinical Status	PHASE1
Clinical Description	An Open-label Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Biodistribution, Radiation Dosimetry and Pharmacokinetics of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
Primary Endpoint	Primary endpoint is maximum tolerated dose (MTD) assessment based on dose-limiting toxicities (DLTs) occurrence [Time Frame: Up to 6 weeks].

Epratuzumab-CL2E-SN-38 [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	42 Day	Low CD22 expression (CD22+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 10⁶ cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.15 mg/dose (2.4 g SN-38 equivalents).
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 2 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	63 Day	Low CD22 expression (CD22+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 10⁶ cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.30 mg/dose (4.8 g SN-38 equivalents).
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 3 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	140 Day	Low CD22 expression (CD22+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 10⁶ cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.15 mg/dose (2.4 g SN-38 equivalents) plus Veltuzumab, 35 ug/dose.
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 4 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Median survival time (MST)	> 161 Day	Low CD22 expression (CD22+)
Method Description	The intravenous WSU-FSCCL models were initiated by intravenous injection of 2.5 x 10⁶ cells, in female severe combined immunodeficient (SCID) mice (Taconic). The dose was 0.30 mg/dose (4.8 g SN-38 equivalents) plus Veltuzumab, 35 ug/dose.
In Vivo Model	WSU-FSCCL CDX model
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903

Revealed Based on the Cell Line Data

Click To Hide/Show 37 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.06 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 2 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.19 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 4 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.34 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 5 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.38 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 6 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.41 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 7 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.46 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 8 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.46 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 9 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.5 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 10 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.51 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 11 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.52 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 12 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.68 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 13 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.73 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 14 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.81 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 15 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.83 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 16 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.84 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 17 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.16 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 18 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.16 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with veltuzumab (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 19 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.22 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 20 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.5 nM	High CD22 expression (CD22+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 21 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.66 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 22 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.68 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Adult B acute lymphoblastic leukemia	RS4;11 cells		CVCL_0093
Experiment 23 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.72 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 24 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.77 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 25 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.84 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with SN38 and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 26 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	. 2.1 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 27 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.21 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 28 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.25 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 29 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.29 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 30 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.45 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (1.33 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 31 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.67 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Childhood B acute lymphoblastic leukemia	697 cells		CVCL_0079
Experiment 32 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.88 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay. Cells were co-incubated with hRS7 (133 nmol/L) and increasing concentrations of Emab-SN-38.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 33 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.92 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 34 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.65 nM	Low CD22 expression (CD22+)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	MN-60 cells		CVCL_1421
Experiment 35 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	135.8 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 36 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	152.3 nM	Moderate CD22 expression (CD22++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 37 Reporting the Activity Date of This ADC					[6]
Efficacy Data	Half Maximal Effective Concentration (EC50)	271 nM	High CD20 expression (CD20+++)
Method Description	Cytotoxicity was determined using the MTS dye reduction assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597

Emab-CL2E-SN38 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	77.9 nM	Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 2 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	135.8 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	152.3 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597

Epratuzumab-SN38 [Phase 1]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 37 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 2 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.19 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 3 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 4 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.34 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 5 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.38 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 6 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.41 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 7 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.46 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 8 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.46 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 9 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.5 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 10 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.51 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 11 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.73 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 12 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.81 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 13 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.83 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (1330 nmol/L).
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 14 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.84 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 15 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.16 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 16 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.16 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 + Vmab (133 nmol/L).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 17 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.5 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 18 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.66 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 19 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.72 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 20 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.77 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 21 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.84 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was Emab-SN-38 alone.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 22 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.21 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 23 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.29 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 24 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.45 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (1330 nmol/L).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 25 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.88 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	To assess the prospect for enhanced cytotoxicity when EmabSN-38 is combined with unconjugated anti-CD20 antibody,cells were co-incubated with veltuzumab (anti-CD20 IgG) and increasing concentrations of EmabSN-38. Humanized RS7 (hRS7) anti-Trop-2 is a nonbinding human IgG1. The test drug was EmabSN-38 + hRS7 (133 nmol/L).
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 26 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.52 nM	High CD22 expression (CD22+++; Median fluorescence=145.0)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Burkitt lymphoma	Daudi cells		CVCL_0008
Experiment 27 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.68 nM	Negative CD22 expression (CD22-; Median fluorescence=7.7)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Follicular lymphoma	WSU-FSCCL cells		CVCL_1903
Experiment 28 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.22 nM	Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 29 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.5 nM	Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	B acute lymphoblastic leukemia	Reh cells		CVCL_1650
Experiment 30 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.68 nM	Low CD22 expression (CD22+; Median fluorescence=22.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Adult B acute lymphoblastic leukemia	RS4;11 cells		CVCL_0093
Experiment 31 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.1 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 32 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.25 nM	Low CD22 expression (CD22+; Median fluorescence=11.2)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Mantle cell lymphoma	JeKo-1 cells		CVCL_1865
Experiment 33 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.67 nM	Low CD22 expression (CD22+; Median fluorescence=16.0)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Childhood B acute lymphoblastic leukemia	697 cells		CVCL_0079
Experiment 34 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.7 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 35 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.92 nM	Moderate CD22 expression (CD22++; Median fluorescence=40.8)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 36 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.2 nM	Moderate CD22 expression (CD22++; Median fluorescence=45.9)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific ADC conjugates against several hematopoietic tumor cell lines. The effect of linkage stability on the cytotoxicity of antibody conjugates as determined by a 4-day MTS assay.
In Vitro Model	EBV-related Burkitt lymphoma	Raji cells		CVCL_0511
Experiment 37 Reporting the Activity Date of This ADC					[7]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.65 nM	Low CD205 expression (CD205+; IHC 1+)
Method Description	In vitro cytotoxicity by MTS assay of SN-38 and specific Emab anti-CD22SN-38 conjugates against several hematopoietic tumor cell lines.
In Vitro Model	Burkitt lymphoma	MN-60 cells		CVCL_1421

References

Ref 1	ADCT-602 in Treating Patients with Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
Ref 2	A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, NCT03698552
Ref 3	A Phase 1 Trial of Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory CD22+ B-Cell Acute Lymphoblastic Leukemia. Blood (2021) 138 (Supplement 1): 1237.
Ref 4	Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial. Blood (2022) 140 (Supplement 1): 521522.
Ref 5	Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
Ref 6	Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012 Jan;11(1):224-34. doi: 10.1158/1535-7163.MCT-11-0632. Epub 2011 Oct 28.
Ref 7	Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther. 2012 Jan;11(1):224-34.

Antibody Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)